环氧丙烷-D3 | 2245-32-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环氧化物
• 中文名称: 环氧丙烷-D3
• 英文名称: d₃-propylene oxide
• 英文别名: 3,3,3-Trideuterio-propylenoxid；Trideuteriomethyl-oxiran；1,2-Propylene-3,3,3-D3 oxide；2-(trideuteriomethyl)oxirane
• CAS: 2245-32-1
• 化学式: C₃H₆O
• 分子量: 61.0562
• InChiKey: GOOHAUXETOMSMM-FIBGUPNXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  4
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  环氧丙烷-D3 、 β-环糊精 在 三乙胺 作用下， 以 水 为溶剂， 反应 2.0h， 以0.26 g的产率得到
  参考文献：
  名称：

  Development and validation of sensitive LC-MS/MS assays for quantification of HP-#x03B2;-CD in human plasma and CSF

  摘要：

  2-Hydroxypropyl-β-cyclodextrin (HP-β-CD), a widely used excipient for drug formulation, has emerged as an investigational new drug for the treatment of Niemann-Pick type C1 (NPC1) disease, a neurodegenerative cholesterol storage disorder. Development of a sensitive quantitative LC-MS/MS assay to monitor the pharmacokinetics (PKs) of HP-β-CD required for clinical trials has been challenging owing to the dispersity of the HP-β-CD. To support a phase 1 clinical trial for ICV delivery of HP-β-CD in NPC1 patients, novel methods for quantification of HP-β-CD in human plasma and cerebrospinal fluid (CSF) using LC-MS/MS were developed and validated: a 2D-LC-in-source fragmentation-MS/MS (2D-LC-IF-MS/MS) assay and a reversed phase ultra performance LC-MS/MS (RP-UPLC-MS/MS) assay. In both assays, protein precipitation and "dilute and shoot" procedures were used to process plasma and CSF, respectively. The assays were fully validated and in close agreement, and allowed determination of PK parameters for HP-β-CD. The LC-MS/MS methods are ∼100-fold more sensitive than the current HPLC assay, and were successfully employed to analyze HP-β-CD in human plasma and CSF samples to support the phase 1 clinical trial of HP-β-CD in NPC1 patients.

  DOI：

  10.1194/jlr.d050278
• 作为产物：
  描述：

  3-bromo-1,1,1-trideuteriopropan-2-ol 在 氢氧化钾 作用下， 生成 环氧丙烷-D3
  参考文献：
  名称：

  Rearrangement and methyl loss from ionized propene oxide and methyl vinyl ether

  摘要：

  DOI：

  10.1021/ja00321a007

文献信息

• VOORHIES K. J.; MCCLENNEN W. H.; MUMFORD N. A., J. LABELLED COMPOUNDS AND RADIOPHARM., 1981, 18, NO 4, 473-478
  作者：VOORHIES K. J.、 MCCLENNEN W. H.、 MUMFORD N. A.

  DOI：——

  日期：——
• TURECEK, F.;MCLAFFERTY, F. W., J. AMER. CHEM. SOC., 1984, 106, N 9, 2528-2531
  作者：TURECEK, F.、MCLAFFERTY, F. W.

  DOI：——

  日期：——
• Rearrangement and methyl loss from ionized propene oxide and methyl vinyl ether
  作者：Frantisek Turecek、Fred W. McLafferty

  DOI：10.1021/ja00321a007

  日期：1984.5
• Development and validation of sensitive LC-MS/MS assays for quantification of HP-#x03B2;-CD in human plasma and CSF
  作者：Hui Jiang、Rohini Sidhu、Hideji Fujiwara、Marc De Meulder、Ronald de Vries、Yong Gong、Mark Kao、Forbes D. Porter、Nicole M. Yanjanin、Nuria Carillo-Carasco、Xin Xu、Elizabeth Ottinger、Myra Woolery、Daniel S. Ory、Xuntian Jiang

  DOI：10.1194/jlr.d050278

  日期：2014.7

  2-Hydroxypropyl-β-cyclodextrin (HP-β-CD), a widely used excipient for drug formulation, has emerged as an investigational new drug for the treatment of Niemann-Pick type C1 (NPC1) disease, a neurodegenerative cholesterol storage disorder. Development of a sensitive quantitative LC-MS/MS assay to monitor the pharmacokinetics (PKs) of HP-β-CD required for clinical trials has been challenging owing to the dispersity of the HP-β-CD. To support a phase 1 clinical trial for ICV delivery of HP-β-CD in NPC1 patients, novel methods for quantification of HP-β-CD in human plasma and cerebrospinal fluid (CSF) using LC-MS/MS were developed and validated: a 2D-LC-in-source fragmentation-MS/MS (2D-LC-IF-MS/MS) assay and a reversed phase ultra performance LC-MS/MS (RP-UPLC-MS/MS) assay. In both assays, protein precipitation and "dilute and shoot" procedures were used to process plasma and CSF, respectively. The assays were fully validated and in close agreement, and allowed determination of PK parameters for HP-β-CD. The LC-MS/MS methods are ∼100-fold more sensitive than the current HPLC assay, and were successfully employed to analyze HP-β-CD in human plasma and CSF samples to support the phase 1 clinical trial of HP-β-CD in NPC1 patients.